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chronic inflammatory mucocutaneous disease. We performed a genome-wide association study
(GWAS) to identify genetic variants associated with HCV-related lichen planus.METHODS: We conducted a GWAS of 261 patients with HCV infection treated at a tertiary medical center in
Japan from October 2007 through January 2013; a total of 71 had lichen planus and 190 had
normal oral mucosa. We validated our findings in a GWAS of 38 patients with HCV-associated
lichen planus and 7 HCV-infected patients with normal oral mucosa treated at a medical cen-
ter in Italy.RESULTS: Single-nucleotide polymorphisms in NRP2 (rs884000) and IGFBP4 (rs538399) were associated
with risk of HCV-associated lichen planus (P < 13 10L4). We also found an association between
a single-nucleotide polymorphism in the HLA-DR/DQ genes (rs9461799) and susceptibility to
HCV-associated lichen planus. The odds ratios for the minor alleles of rs884000, rs538399, and
rs9461799 were 3.25 (95% confidence interval, 1.95–5.41), 0.40 (95% confidence interval,
0.25–0.63), and 2.15 (95% confidence interval, 1.41–3.28), respectively.CONCLUSIONS: In a GWAS of Japanese patients with HCV infection, we replicated associations between pre-
viously reported polymorphisms in HLA class II genes and risk for lichen planus. We also
identified single-nucleotide polymorphisms in NRP2 and IGFBP4 loci that increase and reduce
risk of lichen planus, respectively. These genetic variants might be used to identify patients with
HCV infection who are at risk for lichen planus.Keywords: Inflammation; Risk Factor; Oral Mucosa; Autoimmunity.Abbreviations used in this paper: CI, confidence interval; GWAS,
genome-wide association study; HCV, hepatitis C virus; IFN, interferon;
IGF, insulin-like growth factor; LP, lichen planus; OLP, oral lichen planus;
OR, odds ratio; RCC, renal cell carcinoma; SCC, squamous cell
carcinoma; SNP, single-nucleotide polymorphism.
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http://dx.doi.org/10.1016/j.cgh.2016.12.029Lichen planus (LP) (Figure 1) is a common, chronicinflammatory mucocutaneous disease that affects
mainly middle-aged adults, the prevalence being greater
among women. The oral mucosa, skin, genital mucosa,
and nails are commonly involved, in any combination.
The clinical features of oral LP (OLP) are generally poly-
morphic and usually consist of bilateral and/or multiple
symmetrical lesions, such as reticular, plaque-like,
papular, atrophic, erosive, and bullous, and these are
categorized into 6 types.1 In particular, erosive and atro-
phic forms of OLP manifest painful symptoms, with
weight loss and poor quality of life, and have the poten-
tial of malignant transformation.2,3OLP is a T-cell-mediated autoimmune disease in
which autocytotoxic CD8þ T cells trigger apoptosis of
oral epithelial cells.4 The cytotoxic activity of CD8þ
Figure 1. Clinical pre-
sentations of lichen pla-
nus. (A) Lower lip, (B and
D) left buccal mucosa, (C)
tongue.
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anti–major histocompatibility complex class I mono-
clonal antibody.5
The cause of OLP is unknown, but it seems to be
triggered by stress; genetics; allergic reactions to medi-
cines or dental materials; and by viral infections, such as
with hepatitis C virus (HCV).6 It has been shown that
chronic HCV infection, in addition to causing liver dis-
ease, is responsible for several extrahepatic manifesta-
tions and immune abnormalities, including hematologic,
renal, and mucocutaneous diseases.7–9 Replication of
HCV in the oral mucosa10 and presence of HCV-specific T
cells in OLP specimens11,12 could be involved in the
pathogenesis of OLP. Three recent independent meta-
analyses provide robust evidence that LP and HCV are
associated.13–15
In particular, the relationship between OLP and HCV
has been suggested by studies from Japan and Mediter-
ranean countries, indicating a strong geographic rela-
tionship.16,17 The differences with respect to geographic
area could be associated with the different genetic sus-
ceptibility of the hosts. HCV-associated OLP may be
subdivided into distinct subtypes, because studies have
shown an increased frequency of the HLA class II allele
group, DR6, in patients with OLP with HCV compared
with those without HCV (52% vs 18%; P ¼ .028; relative
risk, 4.93).18,19 The HLA-DR6 allele group is frequently
observed in Italian patients with OLP and hepatitis C.
HCV infection is a major public health problem
because it causes chronic hepatitis, cirrhosis, and hepa-
tocellular carcinoma. In Japan, elderly patients are at a
higher risk for hepatocellular carcinoma, and HCV eradi-
cation has a smaller effect on hepatocarcinogenesis inolder patients.20 OLP can appear or be exacerbated dur-
ing interferon (IFN) therapy for chronic hepatitis C.21,22
The genome-wide association study (GWAS) has
become a powerful tool for investigating the human ge-
netic basis of various diseases. Various genome-based
host variants, such as IFNL3 (also known as IL28B)23–25
and inosine triphosphatase (ITPA)26 genes, have been
found to be valuable markers for treatment response to
hepatitis C and predicting spontaneous viral clearance.
The purpose of this study was to identify the host
genetic factors for HCV-related LP in the Japanese and
Italian populations.
Materials and Methods
Ethical Considerations
The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki and was approved by
the ethics committee of Saga Medical School, Kurume
Medical School, and each participating medical center.
Written informed consent for participation in the study
was obtained from each patient and all samples were
anonymized. All the applied methods in this study were
carried out in accordance with the approved guidelines.
Study Group and Samples
Genomic DNA samples were collected from HCV-
infected Japanese patients with LP (71 patients; mean
age  standard deviation, 67.2  9.6 years; men/women
24/47) and HCV-infected Japanese patients with normal
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tion, 59.8  10.0 years; men/women 83/107) who con-
sulted Kurume University School of Medicine, Fukuoka,
Japan from October 30, 2007, to January 22, 2013
(Table 1). OLP had been diagnosed clinically and histo-
pathologically. The sites of LP in the subjects included oral
mucosa (n ¼ 65), oral and genital mucosa (n ¼ 1), oral
mucosa and skin (n ¼ 3), and skin (n ¼ 2).
Moreover, a replication study was performed using
Italian individuals (38 patients with LP and 7 patients
with normal oral mucosa) who consulted Regional
Transplantation Center, Piedmont, Molinette Hospital,
Turin, Italy.
Genomic DNA was extracted from the peripheral
blood of a total of 261 Japanese HCV-infected patients
using the QIAamp DNA Blood Midi kit (Qiagen, Tokyo,
Japan) in the Department of Virology, Liver Unit, Nagoya
City University Graduate School of Medical Sciences. One
microgram of purified genomic DNA was dissolved in
100 mL of TE buffer (pH 8.0) (Wako, Osaka, Japan), fol-
lowed by storage at 20C until use.
Evaluation of Liver Diseases in Japanese
Patients
A total of 261 subjects were tested for their
liver function. Anti-HCV was measured using a chemilu-
minescent enzyme immunoassay kit (Lumipulse II HCV,Table 1. Characteristics of Studied Japanese Population (n ¼ 2
Characteristics Total
Subjects, n 261
Sex Male/female 107/154
Age Mean  SD, y 61.8  10.4
Site of lichen planus, n Oral mucosa
Oral and genital mucosa
Oral mucosa and skin
Skin
Diagnosis of liver
diseases
Past history of HCV infection 2
AH-C post-IFN (SVR) 2
CH-C 170
CH-C post-IFN (SVR) 23
CH-C post-IFN (SVR) and NAFLD 1
CH-C post-IFN (SVR) and
asymptomatic HBV carrier
1
CH-C and AIH 1
CH-C and ALD 1
CH-C and HCV-related HCC 16
CH-C and CH-B and HCC 2
CH-C post-IFN (SVR) and
HCV-related HCC
1
LC-C 19
LC-C and AIH 1
LC-C and post-IFN (SVR) 1
LC-C and HCV-related HCC 20
AH-C, acute hepatitis C; AIH, autoimmune hepatitis; ALD, alcoholic liver disease;
type C; NAFLD, nonalcoholic fatty liver disease; NS, not significant; SD, standardFujirebio, Tokyo, Japan) and HCV RNA in serum was
analyzed by quantitative polymerase chain reaction
assay (COBAS Amplicor HCVv Monitor v 2.0 Test, COBAS
AmpliPrep/COBAS Taq-Man HCV Test, Roche Molecular
Systems, Branchburg, NJ). Ultrasonographic examination
was performed on all patients. Computed tomography,
liver biopsy, and endoscopic examination for esophageal
or gastric varices were performed on some patients.
We used other possible predictors of liver cirrhosis
progression, including serum albumin, total bilirubin,
prothrombin time, and platelet count.
Single-Nucleotide Polymorphism Genotyping
and Data Cleaning
We genotyped 261 HCV-infected patients with or
without LP using the Affymetrix Genome-Wide Human
SNP Array 6.0 (Affymetrix, Inc, Santa Clara, CA), in
accordance with the manufacturer’s instructions.
The genotype calls for 900K single-nucleotide poly-
morphisms (SNPs) were determined using the Genotyp-
ing Console v4.1 software (Affymetrix, Inc, Santa Clara,
CA) (with Birdseed v1 algorithm) and all samples passed
a heterozygosity check. No duplication or related sam-
ples were identified by identity by descent testing. A
principal component analysis was performed using 261
studied samples together with HapMap samples
(including 43 JPT, 40 CHB, 91 YRI, and 91 CEU samples)61)
Cases with
lichen planus
Control subjects
with normal oral mucosa P value
71 190
24/47 83/107 NS
67.2  9.6 59.8  10.0 < .0001
65
1
3
2
0.77% 1 1.41% 1 0.53%
0.77% 0 0.00% 2 1.05%
65.13% 40 56.34% 130 68.42%
8.81% 8 11.27% 15 7.89%
0.38% 0 0.00% 1 0.53%
0.38% 0 0.00% 1 0.53%
0.38% 0 0.00% 1 0.53%
0.38% 0 0.00% 1 0.53%
6.13% 6 8.45% 10 5.26%
0.77% 0 0.00% 2 1.05%
0.38% 0 0.00% 1 0.53%
7.28% 6 8.45% 13 6.84%
0.38% 1 1.41% 0 0.00%
0.38% 0 0.00% 1 0.53%
7.66% 9 12.68% 11 5.79%
CH-C, chronic hepatitis C; HCC, hepatocellular carcinoma; LC-C, liver cirrhosis
deviation; SVR, sustained virologic response.
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ples showed overlap with that of HapMap-JPT. The
average sample call rate for the 261 studied samples was
98.82% (95.26%–99.55%). Low-quality genotype data
were excluded by the following thresholds for quality
control: SNP call rate <95%, minor allele frequency
<1%, and Hardy-Weinberg equilibrium P value < .0001.
A total of 629,588 SNPs passed the threshold. The scatter
plots for SNP with P < .0001 in the allelic model were
then checked by visual inspection and 35 SNPs were
excluded from further analysis. Finally, a total of 629,553
SNPs were used for further statistical analyses.
A replication study was conducted in Italian in-
dividuals for 3 SNPs (HLA-DR/DQ rs9461799, IGFBP4
rs538399, and NRP2 rs884000) using TaqMan SNP
genotyping assays (Applied Biosystems, Foster City, CA)
on a LightCycle 480 Real-Time PCR System (Roche,
Mannheim, Germany).Single-Nucleotide Polymorphism Imputation
Unobserved genotypes were imputed using the
phased genotype data of 1000 Genomes Project refer-
ence data (Integrated Phase 3, June 2014 released) with
standard software packages, such as IMPUTE version 2
(IMPUTE2) with default parameters. GTOOL was used for
data format conversion from PLINK format to IMPUTE2
format. A 1-Mb window size centered on each candidate
SNP was applied to impute. After imputation, the results
of association test for imputed data were obtained using
PLINK 1.07. SNPs with >1% missing genotype data,Figure 2. Genome-wide view of the single-point association d
Japanese patients with LP and 190 patients with HCV without
allele frequencies among 629,553 SNPs.Hardy-Weinberg equilibrium P value  .001 and samples
including >10% missing genotype were eliminated.
Statistical Analysis
For the association tests, P values, odds ratios (ORs),
and 95% confidence intervals (CIs) between the SNP and
disease phenotype were assessed by chi-square test with
a 2-by-2 contingency table for the allelic model. To avoid
false-positive results caused by multiple testing, the
significance level for the GWAS was set at P ¼ 5  108.
As sensitive analysis, logistic regression analysis with
additive genetic model and gender and age as covariates
was implemented.
Results
Genome-Wide Association Analysis
Figure 2 (Manhattan Plot) shows a genome-wide view
of single point associations of 629,553 SNPs, based on
allele frequencies in a comparison of 71 patients with
HCV with LP and 190 patients with HCV without OLP. A
quantile-quantile plot of the distribution of test statistics
for the comparison of allele frequencies between the 2
groups showed that the inflation factor lambda was
1.027 for all the tested SNPs, and 1.024 when SNPs in the
HLA region (chr6: 29,645,000–33,365,000, GRCh37
hg19) were excluded (Supplementary Figure 2).
Although no SNPs reached the genome-wide significant
level (ie, P < 5  108), the greatest hit association wasata based on allele frequencies in a comparison of 71 HCV
OLP. P values were calculated using the chi-square test for
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downstream from the NRP2 (neuropilin-2) gene,
showing P ¼ 2.84  106 (OR, 3.25; 95% CI, 1.95–5.41)
(Table 2, Supplementary Table 1) and P ¼ 8.60  106
(OR, 3.70; 95% CI, 2.10–6.68) when age and gender were
adjusted. From the HLA class II region (Chr6:
32,256,456–33,258,648, GRCh37 hg19), including the
HLA-DR gene, which has been reported as a disease
susceptibility gene for LP in the Italian population, the
top hit association was observed at rs9461799 showing
P ¼ 3.99  104 (OR, 2.15; 95% CI, 1.41–3.28)
(Supplementary Figure 3) and age- and gender-adjusted
P ¼ 1.39  103 (OR, 2.20; 95% CI, 1.37–3.62). Here,
susceptibility to or resistance against HCV related LP was
evaluated by the OR for the minor allele (ie, OR >1 and
OR <1 indicate susceptible and resistant alleles,
respectively).
We conducted a replication analysis of candidate SNPs
associated with OLP or LP in 45 Italian subjects
(SupplementaryTable 2). The replication analysis in Italian
subjects did not reach significant associations, but showed
the same trend of ORs as shown in Japanese subjects.
High-Density Association Mapping Based on
Genotype Imputation
Genotype imputation was carried out based on
genome-wide SNP typing data using the phased genotype
data of the 1000 Genomes Project reference data with
IMPUTE2 software packages under default parameters.
Among the genetic regions including SNPs with P < 1 
104 in the GWAS, 2 genetic regions included a SNP
showing a stronger association in genotype imputation
based high-density association mapping than the asso-
ciations in GWAS (ie, rs884000 and rs538399)
(Supplementary Figure 4). The SNP rs538399, showing
P ¼ 6.50  105 (OR, 0.40; 95% CI, 0.25–0.63) in the
GWAS, is an intron variant of the insulin-like growth
factor binding protein 4 (IGFBP4) gene.
Discussion
One of the most important issues concerning OLP is
its increased potential for malignant transformation intoTable 2. Associations of rs884000 With HCV-Related Lichen P
rs ID Chr.
Physical
position
(build 37/Hg19) P valuea ORb
95% CI
Low High AA AB
rs884000 2 206680397 2.84E-06 3.25 1.95 5.41 3 30
NOTE. Susceptibility to or resistance against HCV-related LP was evaluated by th
alleles, respectively).
MAF, minor allele frequency.
aP value of Pearson chi-square test for allelic model.
bOR of minor allele from 2-by-2 allele frequency table.oral squamous cell carcinoma (SCC).2,3 There is some
evidence that HCV-positive patients with OLP might be at
higher risk of malignant transformation.27 The relative
risk of malignant transformation for patients with OLP
with HCV, compared with those without HCV infection,
was reported to be 3.16.27
The reported prevalence of HCV-infected patients
with LP shows wide geographic variation and is high in
Japan and Italy.16,17 We consider that the pathogenesis of
OLP in HCV infection is not directly related to the virus
itself, but the response generated by host factors (eg,
immunologic and genetic factors and insulin resistance).
Previous reports indicated that there are no differences
between HCV-infected patients with LP and those
without in terms of viral factors, such as viral load, ge-
notype/subtype, and mutations leading to aa sub-
stitutions in the HCV core region (70 and/or 91) and
IFN-sensitivity-determining region of nonstructural pro-
tein 5A.28,29
Several reports document the impact of IFN on HCV-
associated OLP. As regards the effects of IFN therapy on
LP lesions, there are reports of improvements in lesions,
reports of LP manifestation triggered by IFN, and reports
of exacerbation of LP. Especially, worsening pain and/or
inflammation in OLP in patients receiving IFN therapy
are particular problems that may result in the inability to
complete IFN therapy. It remains difficult to predict the
onset or exacerbation of OLP among HCV infected-
patients. Most recently, we reported successful treat-
ment of HCV-infected OLP by IFN-free therapy with
direct-acting antivirals.30
We found no SNP with genome-wide significance
(P < 5  108). However, 2 SNPs (rs884000 in the NRP2
locus and rs538399 in the IGFBP4 locus) showed nomi-
nal associations in the GWAS and subsequent high-
density association mapping. Moreover, our genetic
analysis also supported the association of the HLA class
II region, including HLA-DR and DQ genes, with HCV-
positive OLP.18,19 The 2 genetic loci found in our study
and HLA genes could be useful as predictors for onset of
OLP among HCV-infected patients. The replication study
in Italian subjects showed the trend similar to Japanese
results.
Neuropilins (NRPs), including NRP1 and NRP2, are
related transmembrane receptors that function aslanus
Cases Control subjects
Allele
A
Allele
B
Associated
geneBB
No
call MAF AA AB BB
No
call MAF
38 0 0.25 3 30 157 0 0.09 G T NRP2
e OR for minor allele (ie, OR >1 and OR <1 indicate susceptible and resistant
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bind members of the class 3 semaphorin family (Sema3A,
Sema3B, and Sema3C), regulators of neuronal guidance,
and of the vascular endothelial growth factor family of
angiogenesis factors.31 NRPs function in many key bio-
logic processes, including in the cardiovascular, nervous,
and immune systems.32 There is substantial evidence
that NRPs serve as mediators of developmental and tu-
mor angiogenesis.31
Recent evidence suggests that NRP2 is expressed in
tumor tissue and plays a role in tumor progression and
metastasis.33,34 NRP2 is highly expressed on the surface
of cancer cells from pancreatic neuroendocrine tumors,35
colorectal carcinomas,33 breast cancer,36 cutaneous
melanoma,37 and oral SCC.38 NRP2 expression also cor-
relates with lymph node metastasis in breast cancer36
and papillary thyroid carcinoma.34 Cao et al39 showed
that NRP2 promotes metastasis of renal cell carcinoma
(RCC) and pancreatic cancer in mouse and zebrafish
models and showed a mechanism through which NRP2
expressed on cancer cells interacts with a-5 integrin on
endothelial cells to mediate vascular adhesion and
extravasation.
The insulin-like growth factor system (IGFs) consists
of 2 peptides (IGF-I and -II), 2 main receptors (IGF-IR
and IGFIIR), 6 different IGF binding proteins (IGFBP1-6),
and 4 IGFBP-related peptides (IGFBP Rp1-4). IGFs have
multiple functions regarding cellular growth, survival,
and differentiation under different physiologic and
pathologic conditions.40 IGFBP4 is an important member
of the IGF system. IGFBP4 has been reported to play a
critical role in cardiomyocyte differentiation of embry-
onic stem cells.41
Several cancer cell lines, including from multiple
myeloma, neuroblastoma, and mesothelioma, and can-
cers of the lung, gastric, thyroid, breast, prostate, and
colon have been reported to express IGFBP4.42 Ueno
et al43 initially showed that the expression of IGFBP4
was significantly lower in primary RCC and higher in
metastatic RCC, compared with normal human kidney
tissue, and that IGFBP4 transfectants promoted cell
growth (in vitro and in vivo), invasion, and motility in
primary RCC.
In the present study, 4 of 71 Japanese patients with
LP (5.6%), 3 women and 1 man, developed oral SCC.
One of the 4 subjects was a 84-year-old woman who
suffered from HCV-related liver cirrhosis. She devel-
oped oral verrucous carcinoma, arising OLP-coexisting
vulvo-vaginal gingival syndrome and esophageal
SCC.44 Another, in whom sustained virologic response
was obtained by IFN therapy, was a 73-year-old man
who suffered from chronic hepatitis C and hyperten-
sion. He developed tongue cancer and Graves oph-
thalmopathy during pegylated IFN plus ribavirin
therapy. The third patient was a 57-year-old woman
who suffered from chronic hepatitis C during IFN
therapy. She developed tongue cancer arising from OLP.
The fourth was a 67-year-old woman who sufferedfrom chronic hepatitis C. She developed tongue cancer
arising from OLP after treatment with pegylated IFN
plus ribavirin. Only she had the risk allele at rs88400 in
NRP2 but she did not have the resistance allele at
rs538399 in IGFBP4. No patients in the control group
developed oral cancer.
We reported previously that insulin resistance might
be involved in the development of multiple primary
cancers in patients with oral SCC and HCV infection45
and might cause OLP and extrahepatic manifesta-
tions.46,47 The prevalence of extrahepatic malignant tu-
mors was significantly higher in patients with OLP
(29.4%) than in patients without (4.3%).47 Two SNPs
(rs884000 on NRP2 and rs538399 on IGFBP4) may play
a role in the malignant transformation of OLP.
Our study had some limitations. The sample size was
relatively smaller than that for the conventional GWAS
for diagnostic criteria. However, to the best of our
knowledge, our GWAS for HCV-related LP is the first such
report.
In conclusion, we identified novel associations of
rs884000 in NRP2, rs538399 on IGFBP4, and supported
the association of the HLA-DR/DQ genes, with HCV-
positive LP in the Japanese and Italian population. Our
data suggest that these genes may be involved in the
development of LP and malignant transformation and
useful as a predictive marker for the onset of OLP with
IFN therapy among HCV infected-patients.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2016.12.029.References
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Supplementary
Figure 1. Principal compo-
nent analysis of 261 studied
samples together with
HapMap samples (including
43 JPT, 40 CHB, 91 YRI,
and 91 CEU samples).
June 2017 GWAS for HCV-Related LP 944.e1
Supplementary
Figure 2.Quantile-Quan-
tile plot of the allele-based
Chi-square test statistics
for the GWAS results. The
dots represent the P
values of each SNP that
passed the quality control
filters. The inflation factor l
was estimated to be 1.027
for all the tested.
Supplementary
Figure 3. Regional Manhattan
plot of the HLA class II region
(Chr6: 32,256,456 - 33,258,648,
GRCh37 hg19) in the GWAS.
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Supplementary Figure 4. High density association mapping based on genotype imputation around (A) rs884000, and
(B) rs538399.
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Supplementary Table 1. Associations of GWAS for HCV-Related LP Cases and Control Subjects
rs ID Chr.
Physical position
(build 37/Hg19) P valuea ORb
95% CI Cases Control subjects
Allele A Allele B
Associated
geneLow High AA AB BB No call MAF AA AB BB No call MAF
rs241501 1 49765438 5.49E-05 0.39 0.25 0.62 1 26 44 0 0.20 31 84 75 0 0.38 G T AGBL4
rs568052 1 55524842 6.37E-05 0.18 0.07 0.46 0 5 66 0 0.04 4 56 130 0 0.17 C T PCSK9
rs10915880 1 224041034 1.41E-05 4.87 2.24 10.59 3 12 56 0 0.13 1 9 180 0 0.03 A G TP53BP2
rs17363620 2 5734639 4.59E-05 3.18 1.78 5.67 1 25 45 0 0.19 0 26 163 1 0.07 A T Intergenic region
rs16863981 2 5736321 4.18E-05 3.20 1.79 5.70 1 25 45 0 0.19 0 26 164 0 0.07 A T Intergenic region
rs13019074 2 5737785 8.39E-05 3.09 1.72 5.53 1 24 45 1 0.19 0 26 163 1 0.07 A C Intergenic region
rs11693312 2 5745057 2.51E-05 2.92 1.75 4.88 1 32 38 0 0.24 1 35 154 0 0.10 A G Intergenic region
rs6432151 2 5760116 4.54E-05 2.73 1.66 4.49 1 34 36 0 0.25 1 40 149 0 0.11 A T Intergenic region
rs1437040 2 5760247 4.54E-05 2.73 1.66 4.49 1 34 36 0 0.25 1 40 149 0 0.11 A G Intergenic region
rs6710579 2 5762278 7.94E-05 2.67 1.62 4.39 1 33 36 1 0.25 1 40 148 1 0.11 G T Intergenic region
rs7610518 3 46161631 7.09E-05 0.41 0.27 0.64 3 26 42 0 0.23 30 97 63 0 0.41 C T XCR1
rs4859240 3 182476614 9.38E-05 0.40 0.25 0.64 3 21 47 0 0.19 29 81 78 2 0.37 A G Intergenic region
rs11943343 4 117407994 9.30E-05 5.06 2.07 12.34 1 12 58 0 0.10 0 8 181 1 0.02 A G Intergenic region
rs13148375 4 177557439 6.03E-05 2.88 1.69 4.90 2 27 41 1 0.22 3 28 158 1 0.09 A C Intergenic region
rs2067833 6 53330356 3.51E-05 2.33 1.55 3.49 16 30 25 0 0.44 14 67 109 0 0.25 A G Intergenic region
rs2189887 8 5501607 3.25E-05 0.23 0.11 0.48 0 8 63 0 0.06 8 63 118 1 0.21 A T Intergenic region
rs391583 8 37178897 4.37E-05 0.36 0.22 0.60 1 20 50 0 0.15 26 76 88 0 0.34 C T Intergenic region
rs6995149 8 37179494 3.50E-05 0.36 0.22 0.59 1 20 50 0 0.15 27 75 88 0 0.34 C G Intergenic region
rs436802 8 37180035 2.33E-05 0.34 0.21 0.57 1 19 50 1 0.15 27 75 88 0 0.34 C T Intergenic region
rs7865508 9 332639 8.51E-05 2.54 1.58 4.09 6 27 38 0 0.27 3 43 143 1 0.13 C T DOCK8
rs7870726 9 13530105 5.89E-05 3.18 1.77 5.73 4 18 49 0 0.18 1 23 166 0 0.07 C T Intergenic region
rs12343442 9 15212216 5.44E-05 4.70 2.08 10.62 1 14 56 0 0.11 0 10 180 0 0.03 G T TTC39B
rs7087214 10 106193598 7.40E-05 2.59 1.60 4.19 5 28 38 0 0.27 5 37 148 0 0.12 A C CCDC147
rs8181424 10 128602101 8.96E-05 2.32 1.51 3.55 9 33 29 0 0.36 2 70 118 0 0.19 C T DOCK1
rs7294533 12 54612774 6.06E-05 2.75 1.66 4.58 6 22 43 0 0.24 2 35 153 0 0.10 C T CBX5
rs7315138 12 62388915 6.90E-05 2.24 1.50 3.34 18 28 25 0 0.45 13 76 101 0 0.27 A T FAM19A2
rs202092 13 30814313 9.82E-05 4.15 1.93 8.93 1 15 55 0 0.12 0 12 177 1 0.03 C T KATNAL1
rs7140779 14 49946421 3.64E-05 2.50 1.60 3.88 10 27 31 3 0.35 5 56 128 1 0.17 C T Intergenic region
rs11624787 14 53288450 6.27E-05 0.42 0.27 0.65 4 27 40 0 0.25 34 96 57 3 0.44 C G FERMT2
rs538399 17 38610665 6.50E-05 0.40 0.25 0.63 2 25 42 2 0.21 26 99 64 1 0.40 C T IGFBP4
rs3862706 18 57728033 6.09E-05 4.31 2.00 9.28 1 15 53 2 0.12 0 12 178 0 0.03 G T Intergenic region
rs4812826 20 42972275 8.26E-05 2.18 1.47 3.23 23 37 11 0 0.58 28 93 69 0 0.39 A G R3HDML
rs5997363 22 28794069 1.25E-05 7.56 2.64 21.61 2 9 60 0 0.09 0 5 185 0 0.01 A G TTC28
rs713727 22 49794342 7.44E-05 3.73 1.87 7.43 0 20 51 0 0.14 1 14 175 0 0.04 C T Intergenic region
NOTE. GWAS result P value < 10-4. Susceptibility to or resistance against HCV-related LP was evaluated by the OR for minor allele (ie, OR >1 and OR <1 indicate susceptible and resistant alleles, respectively).
MAF, minor allele frequency.
aP value of Pearson chi-square test for allelic model.
bOR of minor allele from 2-by-2 allele frequency table.
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Supplementary Table 2. Replication Study of rs9461799, rs538399, and rs884000 with HCV-Related LP in Italian Patients
rs ID Chr.
Physical
position
(build 37/Hg19) P valuea ORb
95% CI Cases Control subjects
Allele
A
Allele
B
Associated
geneLow High AA AB BB
No
call RAF AA AB BB
No
call RAF
rs9461799 6 32689529 4.74E-01 1.57 5.42 0.454 12 13 10 3 0.53 1 3 2 0 0.42 T C HLA class II
rs538399 17 38610665 9.14E-01 0.91 4.81 0.173 0 13 22 3 0.19 0 2 3 2 0.20 G A IGFBP4
rs884000 2 206680397 7.95E-01 1.33 11.7 0.152 1 6 30 1 0.11 0 1 5 1 0.08 C A NRP2
NOTE. Susceptibility to or resistance against HCV-related LP was evaluated by the OR for minor allele (ie, OR >1 and OR <1 indicate susceptible and resistant
alleles, respectively).
RAF, risk allele frequency.
aP value of Pearson chi-square test for allelic model.
bOR of minor allele from 2-by-2 allele frequency table.
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